GlassScriptPhysician profile
Edward Albert G Balbas
NPI 1629062435
$771.87
in general payments reported to CMS, 2019-2025
10 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.57 · 2022: $17.04 · 2023: $33.90 · 2024: $169 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $142.28 | 2024 | Amyvid |
| Ucb, INC. | $136.54 | 2025 | Fintepla |
| Ani Pharmaceuticals, INC. | $131.98 | 2024-2025 | Purified Cortrophin Gel |
| Biogen, INC. | $125.00 | 2025 | Tysabri |
| Life Molecular Imaging LTD | $90.56 | 2025 | Neuraceq |
| Electronic Waveform Lab, INC. | $55.22 | 2021 | |
| Argenx US, INC. | $33.90 | 2023 | Vyvgart Hytrulo |
| Boston Scientific Corporation | $24.89 | 2021 | |
| Horizon Therapeutics Plc | $17.04 | 2022 | |
| Trevena, INC. | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Albert Balbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.